Say Hello!
Don’t be shy.

   

News

Medilink Midlands has announced that its newly forged Board of Directors has appointed Dr Darren Clark as Chief Executive Officer and member of the Board of Directors, effective immediately. Darren previously held the position of Chief Executive Officer at Medilink East Midlands. Darren joined Medilink East...

(L-R) Sarah Hardy, Archangels; Carol Thomson, BDD | Photo credit: Jamie Williamson Backing to fund the further expansion of formulation and manufacturing capabilities underpinned by strategic senior appointments Innovative Scottish-based drug delivery company, Bio-Images Drug Delivery Limited (BDD), has positioned itself for rapid growth with a further round of...

Macclesfield-based proteomic-data science and diagnostics company, Kinomica, has secured £3.9m in funding for pioneering technology that could prove integral to the development of new drug treatments. KScan™, a next-generation biomarker and molecular diagnostics platform, has been designed to aid the development of kinase inhibitor drugs for...

A University of Dundee spinout company developing treatments for eczema, rheumatoid arthritis and other inflammatory conditions has completed its first round of private investment. BioCity Accelerator alumni, In4Derm Ltd, is an innovative drug discovery company developing the next generation of topical and oral therapies for widespread...

Next-generation yeast strain developer and BioCity client company, Phenotypeca Ltd, has been awarded funding from the Future Vaccine Manufacturing Research Hub (Vax-Hub) to conduct a feasibility study that will exploit the genetic diversity of baker’s yeast to optimise virus-like particles (VLPs) for vaccine production. Vax-Hub launched...

On 27 November, eight innovative start-ups from the Oxford AHSN Accelerator, delivered by BioCity presented their progress and their pitches for future investment to a panel of experts from Oxford AHSN, BioCity and industry. Their pitches were the culmination of the second Oxford AHSN Accelerator programme, delivered by...

BioCity Glasgow based biotechnology company ILC Therapeutics (ILCT) today announced that it has secured significant investment from its first global investor Medical Incubator Japan (MIJ). The Scottish life sciences company, which has received international attention through its work exploring COVID-19 therapeutic treatments with the University...